Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30

$12.95−0.45 (-3.36%)

Close on Nov 12, 2026Market cap $908.68MP/E 323.8Yield –

Pharming EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Pharming's EV/EBITDA was 30.8× on Nov 11, 2026, against 30.2× a year earlier. Over the last 4 years it ranged from 3.7× to 39.6×, with a median of 25.5×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	30.8×	−8.0
2024	Feb 29, 2024	38.8×	+9.0
2023	Dec 29, 2023	29.8×	+3.5
2022	Dec 30, 2022	26.2×	+21.8
2021	Dec 31, 2021	4.4×	−7.6
2020	Dec 31, 2020	12.1×	–

Where these numbers come from

Parsed from the XBRL in Pharming's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PHAR.

Compare: PHAR vs MIRM · PHAR vs TVTX · PHAR vs RARE · PHAR vs XERS · PHAR vs ZLAB

Revenue growth26.6% · median 38.4%

Gross margin87.9% · median 87.4%

Operating margin6.9% · median -63.0%

Net margin0.8% · median -44.9%

Company	Revenue	Growth
RARE	$730.00M	+15.8%
TVTX	$651.04M	+49.4%
MIRM	$618.07M	+44.0%
ZLAB	$441.73M	+0.0%
PHAR	$376.13M	+26.6%
XERS	$368.26M	+38.4%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 50,000
Held by institutions: 0.3%
Auditor: Deloitte Accountants B.V.
SEC CIK: 1828316

Advertisement
300 × 250

See a number that looks wrong?